In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Basilea ceftobiprole enters Phase III

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Basilea initiates a Phase III program for its antibiotic ceftobiprole (BAL5788) for use in complicated skin and skin structure infections, the firm announces Nov. 4. The Swiss company, a spin-off of Roche, describes the agent as "the first of a new generation of anti-[methicillin-resistant Staphylococcus aureus] cephalosporins" that will "combine the well-established advantages of the cephalosporin antibiotic class with an enhanced gram-positive antibacterial spectrum." Ceftobiprole was designed to bind to mutated targets in MRSA. A 700-patient skin/skin structure infections study versus vancomycin is ongoing, with additional studies planned in other severe infection indications. Ceftobiprole has fast-track status for CSSIs due to MRSA and for hospital-acquired pneumonia due to MRSA...

You may also be interested in...



Licensing In Brief

 

Podcast: Scrip’s Asia Team Dissects Pharma’s Response To Coronavirus

Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.

Lilly’s Cyramza Wins Slim Nod, But Steba’s Tookad Falls Hard At US FDA Panel

Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.


Topics

UsernamePublicRestriction

Register

PS002692

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel